Clinical Cancer Research, Vol 4, Issue 1 189-196, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers

JP Peyrat, L Vanlemmens, J Fournier, G Huet, F Revillion and J Bonneterre
Laboratoire d'Oncologie Moleculaire Humaine, Centre Oscar Lambret, Lille, France.

We measured the levels of p53 and urokinase-type plasminogen activator (uPA) in 634 tumor tissues from 634 different node-negative primary breast cancer patients who underwent locoregional surgery in the Center Oscar Lambret between July 1989 and September 1994. p53 and uPA were assayed using commercially available kits in cytosols prepared for estradiol receptor (ER) and progesterone receptor (PgR) assays. The optimum clinical thresholds were chosen for prognostic studies: 4 ng/ml for p53 and 0.5 ng/ml for uPA. p53 was elevated in 13.7% of the tumors, and uPA was elevated in 27.5% of the tumors; they were negatively related (chi 2 test) to ER and PgR and positively related to histoprognostic grading (HPG) and tumor diameter. uPA was negatively correlated to ER and PgR, and p53 and uPA were positively correlated to each other (P = 0.0001; Spearman test). In the prognostic studies, the 316 patients who did not receive adjuvant chemotherapy were included to avoid treatment interference; this number corresponds to all of the patients operated on between 1989 and 1992. The mean duration of follow-up of living patients was 4 years. In overall survival studies, Cox univariate analyses demonstrated a prognostic value of p53 (P = 0.011; risk ratio, 1.59), uPA (P = 0.038; risk ratio, 2.32), PgR, HPG, and tumor diameter. In Cox multivariate analyses, only HPG had a statistically significant prognostic value. In relapse-free survival studies, univariate analyses demonstrated prognostic values of uPA (P = 0.0011) and of age, and both parameters retained their prognostic value in multivariate analyses (uPA: P = 0.0004). This study demonstrates not only that p53 and uPA have prognostic value but also that these two parameters are linked to other classical clinical, histological, or biological prognostic parameters, as well as to each other. Moreover, because uPA is of prognostic value in multivariate relapse-free survival studies, uPA is an important prognostic factor in node-negative breast cancer patients.

This article has been cited by other articles:

				P. Shetty, T. Velusamy, Y. P. Bhandary, R. S. Shetty, M.-C. Liu, and S. Shetty Urokinase Expression by Tumor Suppressor Protein p53: A Novel Role in mRNA Turnover Am. J. Respir. Cell Mol. Biol., September 1, 2008; 39(3): 364 - 372. [Abstract] [Full Text] [PDF]

				A. Chotteau-Lelievre, F. Revillion, V. Lhotellier, L. Hornez, X. Desbiens, V. Cabaret, Y. de Launoit, and J.-P. Peyrat Prognostic Value of ERM Gene Expression in Human Primary Breast Cancers Clin. Cancer Res., November 1, 2004; 10(21): 7297 - 7303. [Abstract] [Full Text] [PDF]

				M. P. Look, W. L. J. van Putten, M. J. Duffy, N. Harbeck, I. J. Christensen, C. Thomssen, R. Kates, F. Spyratos, M. Ferno, S. Eppenberger-Castori, et al. Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients J Natl Cancer Inst, January 16, 2002; 94(2): 116 - 128. [Abstract] [Full Text] [PDF]

				T. J. Delebecq, H. Porte, F. Zerimech, M.-C. Copin, V. Gouyer, E. Dacquembronne, M. Balduyck, A. Wurtz, and G. Huet Overexpression Level of Stromelysin 3 Is Related to the Lymph Node Involvement in Non-small Cell Lung Cancer Clin. Cancer Res., March 1, 2000; 6(3): 1086 - 1092. [Abstract] [Full Text]

				M. Hebbar, F. Revillion, M.-M. Louchez, C. Fournier, J. Bonneterre, and J.-P. Peyrat Prognostic Value of Circulating Soluble E-Selectin Concentrations in Node-negative Breast Cancer Patients Clin. Cancer Res., June 1, 1999; 5(6): 1427 - 1433. [Abstract] [Full Text] [PDF]